IRAG2

Across TCGA pan-cancer cohorts, IRAG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IRAG2 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IRAG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IRAG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where IRAG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.328	0.539	.012	10	view →
LUAD	DFS	Median	II,III,IV	0.684	0.335	.008	9	view →
HNSC	DFS	Quartile	II,III,IV	0.886	0.983	.046	2	view →
CCRCC	OS	Median	II,III,IV	1.000	0.449	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IRAG2–PDAC (DFS)

Open the PDAC breakdown →